MOWOOT

Up to 24% of the general population suffer from chronic or re-occurring constipation, especially neurogenic patients (up to 80%) and the elderly (up to 60%).
Current solutions are either pharmacological or invasive, have side effects and leave patients and professionals unsatisfied.

MOWOOT is a novel, purely physical, non-drug, non-invasive solution to constipation in the form of a CE-certified class IIa medical device.

With only 10-20 minutes of daily treatment MOWOOT generates an exo-peristaltic effect that moves the faeces and solves constipation in a natural way. Clinically proven.

Milestones achieved so far:

- Product developed & on the market
- CE & ISO certified
- IP protected
- Clinical proof
- Proof of business with first sales in ES, GER, UK & NL
- Distributor agreements & pipeline
- Private healthcare reimbursement
- Clear Roadmap

MOWOOT is the first purely physical, non-drug, non-invasive medical device targeting intestinal transit disorders.

Beachhead Target Indication:
- Neurogenic Bowel Disorders (NBD)
Global Annual Market $365M w/ CAGR 3%

Future Indications:
-Opioid-Induced-Constipation (OIC)
Global Annual Market $3.7B w/ CAGR 32%
- Idiopathic Chronic Constipation (ICC)
Global Annual Market $12.6B w/ CAGR 7.1%
- Health & Wellness (OTC device)
Global Annual Market $64B w/ CAGR 4.4%

Up to 24% of the general population suffer from chronic or re-occurring constipation, especially neurogenic patients (up to 80%) and the elderly (up to 60%).
Current solutions are either pharmacological or invasive, have side effects and leave patients and professionals unsatisfied.

MOWOOT is a novel, purely physical, non-drug, non-invasive solution to intestinal transit disorders & chronic constipation in the form of a CE-certified class IIa medical device.

With only 10-20 minutes of daily treatment MOWOOT generates an exo-peristaltic effect via a series of pneumatic elements that inflate and deflate wave-like along the large intestine and hence moves the faeces, increases colonic secretion and solves constipation in a natural way.

Clinically proven. CE certified. On the market and in use by KOL institutions in Spain, Germany, UK and the Netherlands.

- professional manual colon-specific massage (physiotherapists, nurses & caregivers)
- laxatives (pharma companies)
- constipation drugs (pharma companies)
- trans anal irrigation/ enemas (Colplast, Wellspect, Braun)
- surgical solutions like STOMA, SARS, SNS, etc. (Medtronic, Coloplast,)

MOWOOT is a novel, purely physical, non-drug, non-invasive solution, without the side effects of the competitors and also cheaper than current approaches.

So far $ 2,900,000 have been raised, in private (26%) and mainly public (74%) funds.

Classic medical device business model:

sales to regional distributors; final payour is the private and public healthcare system (reimbursement)

Expanding geographical footprint in the main EU reimbursed markets and reaching breakeven.

Use of funds:
33% Clinical Budgets
29% Marketing & Business development
16% Regulatory & IP
14% General Expenses
8% Working Capital

Equity investment

The project has been systematically de-risked over the las 6 years. The remaining risk is the market adoptionb, which is under control with first EU KOL institutions and medical guidelines already recommending MOWOOT.

- design Health Barcelona (MOEBIO)
- Bioentrepreneur XXI (Bioemprendedor XXI)
- Mass Challenge UK

- 2020: most "investable" company in category medical devices at RESI EUROPE 2020 investor conference
- 2020: 2nd most voted company of all categories at RESI EUROPE 2020 investor conference
- 2019: "Impact Business Award" from Ship2B Social Impact Foundation
- 2017: Triple award winner at European Health Catapult (EIT Health)
- 2017: awarded € 1,250,00 Horizon2020 SME Instrument Phase II grant from European Comission
- etc.

Yes